AURO-DIMETHYL FUMARATE CAPSULE (DELAYED RELEASE)

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DIMETHYL FUMARATE

Pieejams no:

AURO PHARMA INC

ATĶ kods:

L04AX07

SNN (starptautisko nepatentēto nosaukumu):

DIMETHYL FUMARATE

Deva:

240MG

Zāļu forma:

CAPSULE (DELAYED RELEASE)

Kompozīcija:

DIMETHYL FUMARATE 240MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Produktu pārskats:

Active ingredient group (AIG) number: 0154210002; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2023-08-28

Produkta apraksts

AURO-DIMETHYL FUMARATE (Dimethyl Fumarate Delayed-Release Capsules)
Page 1 of 43
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
AURO-DIMETHYL FUMARATE
Dimethyl Fumarate Delayed-Release Capsules
Delayed-Release Capsules, 120 mg and 240 mg, Oral
House Standard
Antineoplastic and Immunomodulating Agents
Auro Pharma Inc.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8
Canada
Date of Initial Authorization:
August 22, 2023
Submission Control Number: 269223
AURO-DIMETHYL FUMARATE (Dimethyl Fumarate Delayed-Release Capsules)
Page 2 of 43
RECENT MAJOR LABEL CHANGES
Not Applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES.........................................................................................
2 TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1 INDICATIONS
......................................................................................................................
4
1.1 Pediatrics
.......................................................................................................................
4
1.2
Geriatrics........................................................................................................................
4
2 CONTRAINDICATIONS
.........................................................................................................
4
4 DOSAGE AND ADMINISTRATION
........................................................................................
4
4.1 Dosing Considerations
...................................................................................................
4
4.2 Recommended Dose and Dosage Adjustment
............................................................... 5
4.4 Administration
......................................................